Related Experiment Videos
Safety profile of interferon-alpha therapy
1Division of Clinical Trials Design and Analysis, Food and Drug Administration, Rockville, MD 20892, USA.
Seminars in Oncology
|March 3, 1998
Summary
Recombinant interferon-alpha (IFN-alpha) therapies are approved for various cancers and hepatitis, but postmarketing surveillance reveals new toxicities. Management strategies for side effects like depression and fatigue are needed.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Recombinant interferon-alpha (IFN-alpha) has FDA approval for treating hairy cell leukemia, hepatitis, Kaposi's sarcoma, chronic myelogenous leukemia, and melanoma.
- IFN-alpha2a and IFN-alpha2b are the approved forms, demonstrating clinical efficacy and safety.
Purpose of the Study:
- To review adverse reactions associated with interferon-alpha therapy.
- To highlight newly identified toxicities and common side effects.
- To emphasize the need for improved management strategies for IFN-alpha side effects.
Main Methods:
- Postmarketing surveillance of adverse reactions.
- Review of clinical efficacy and safety profiles.
- Analysis of reported side effects from interferon-alpha therapy.
Main Results:
- Common adverse events include flu-like symptoms, fatigue, anorexia, and central nervous system/psychiatric reactions.
- The incidence of depression associated with IFN-alpha therapy is increasingly recognized.
- Chronic fatigue, anorexia, and neuropsychiatric reactions can be dose-limiting.
Conclusions:
- Continued monitoring of interferon-alpha therapy reveals significant adverse events.
- Depression and other neuropsychiatric effects are critical toxicities.
- Novel approaches are required to effectively manage and minimize IFN-alpha-related side effects.